Business Area

Home > About Hanmi > Company Profile > Business Area

Domestic business

Hanmi pharmaceutical company has the most medical representatives among pharmaceutical companies based on superior sales infra structure. Slimmer has shown the sales power of Hanmi catching up original product Reductil. It is expected that Hanmi will grow more as they launch 22 new products in 2009 based on the sales power. Besides Hanmi pharmaceutical company is investing intensively on two core platform technologies which are LASPCOVERY and ORASCOVERY to develop creative new medicines. These new technologies have become the prime movers for continuing growth.

Global business

Hanmi achieved 58 million dollar export in 2007, 65 million dollar export in 2008 and is focusing on European, American market and also Japanese market as the plant for Cepha antibiotic finished product is about to be completed in Pyeong teak Kyeong gi province in 2007. ‘Hanmi fine chemicals’, Hanmi’s affiliate, producing API specially is exporting API to 30 countries such as Middle East Asia, Japan, South America, China, and also Europe. Hanmi Beijing as known as a successful business model in China has been growing rapidly since it was established in 1996. Hanmi will be a global pharmaceutical company that makes money in global market rather than in domestic market through accumulated information and endless innovation of technology such as a development of new dosage form and new materials.